Tebipenem pivoxil (L084) hydrochloride 是一种抗多种致病菌的具有口服活性的抗生素。 Tebipenem pivoxil hydrochloride 结合青霉素结合蛋白 (PBP),从而抑制细胞壁合成。
生物活性 | Tebipenem pivoxil (L084) hydrochloride is an orally activeantibioticagainst a variety of pathogenic bacteria. Tebipenem pivoxil hydrochloride binds penicillin-binding protein (PBP), thereby inhibiting cell wall synthesis[1]. |
体外研究 (In Vitro) | Tebipenem pivoxil hydrochloride (0-128 μg/mL, 18–24 h) displays excellent antibacterial activity against a variety of pathogenic bacteria[1].
Cell Viability Assay[1] Cell Line: | Gram-positive and Gram-negative bacteria | Concentration: | 0-128 μg/mL | Incubation Time: | 18–24 h | Result: | Showed inhibition with MIC50s below 64 μg/mL against tested Gram-positive and Gram-negative bacteria. |
|
体内研究 (In Vivo) | Tebipenem pivoxil (L084) (0-4.00 g/kg; p.o.; once) hydrochloride shows minimal lethal dosage (MLD) of 4.00 g/kg and the maximum tolerance dosage (MTD) of 3.40 g/kg in mice[1]. Tebipenem pivoxil (50 and 100 mg/kg; p.o.; once) hydrochloride significantly protects the sepsis mice challenged with various pathogenic bacteria[1].
Animal Model: | KM mice weighing 18–22 g[1] | Dosage: | 2.89, 3.40 and 4.00 g/kg | Administration: | Oral administration (tablet), once | Result: | Within the 14-day observation period, only one mouse was dead in the maximum oral dosage (4.00 g/kg). The minimal lethal dosage (MLD) was 4.00 g/kg and the maximum tolerance dosage (MTD) in the mice was 3.40 g/kg. Showed dose-dependent liver and kidney damage. |
Animal Model: | ICR mice, sepsis mouse models[1] | Dosage: | 50 and 100 mg/kg | Administration: | Oral administration (tablet), once | Result: | Significantly increased the survival number of the sepsis mice within a 168 h observation period. |
|
Clinical Trial | |
分子量 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |